FDA-cleared profile

Bunkerhill Contrast CAC

BunkerHill Health · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.

Clinical role
Adjunctive physician-review support for detection, localization, and quantification of coronary calcium; not stand-alone diagnosis.
Images and patients
CT/CTA · Chest/coronary arteries
Key limitation
Keep in mind: The intended input is non-gated contrast-enhanced chest CT with slice thickness up to 5 mm and adults age 30 or older. The ROI is informational only; outputs do not replace the original report or scan and are not for stand-alone use. Pivotal testing was retrospective and its exact case count is not stated in the packet.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/coronary arteries Input: DICOM non-gated, contrast-enhanced chest CT images from adult patients age 30 or older, with slice thickness up to 5 mm.
  • Who uses it?Intended users: Qualified medical professionals, such as interpreting physicians.
  • What does the software produce?Output: Informational ROI on a copy of the original CT showing detected coronary calcium; estimated overall calcium volume score in mm3; binary presence/absence output; results can be viewed in a patient report or diagnostic viewer/PACS, with optional copy/insert or DICOM Secondary Capture.
  • What is its most important limitation?Key limitation: The intended input is non-gated contrast-enhanced chest CT with slice thickness up to 5 mm and adults age 30 or older. The ROI is informational only; outputs do not replace the original report or scan and are not for stand-alone use. Pivotal testing was retrospective and its exact case count is not stated in the packet.

Clinical takeaway. Clinical role: Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: stand-alone retrospective pivotal study from multiple sites across three U.S. geographic regions; exact pivotal sample size is not stated. Endpoints covered detection, localization/ROI, precision/recall, correlation, and volume agreement. A 50-case bridging study compared volume on contrast-enhanced images with the same patients' non-contrast images.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Detect, localize, and estimate the burden of coronary artery calcification on contrast-enhanced chest CT during clinical care.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Adjunctive physician-review support for detection, localization, and quantification of coronary calcium; not stand-alone diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM non-gated, contrast-enhanced chest CT images from adult patients age 30 or older, with slice thickness up to 5 mm.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Informational ROI on a copy of the original CT showing detected coronary calcium; estimated overall calcium volume score in mm3; binary presence/absence output; results can be viewed in a patient report or diagnostic viewer/PACS, with optional copy/insert or DICOM Secondary Capture.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Medical facility and clinical-care workflow; exact facility type is not further specified.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Qualified medical professionals, such as interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The intended input is non-gated contrast-enhanced chest CT with slice thickness up to 5 mm and adults age 30 or older. The ROI is informational only; outputs do not replace the original report or scan and are not for stand-alone use. Pivotal testing was retrospective and its exact case count is not stated in the packet.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA packet: stand-alone retrospective pivotal study from multiple sites across three U.S. geographic regions; exact pivotal sample size is not stated. Endpoints covered detection, localization/ROI, precision/recall, correlation, and volume agreement. A 50-case bridging study compared volume on contrast-enhanced images with the same patients' non-contrast images.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: stand-alone retrospective pivotal study from multiple sites across three U.S. geographic regions; exact pivotal sample size is not stated. Endpoints covered detection, localization/ROI, precision/recall, correlation, and volume agreement. A 50-case bridging study compared volume on contrast-enhanced images with the same patients' non-contrast images.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
95.7% (95% CI: 92.4%, 99.1%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
92.9% (95% CI: 88.2%, 97.6%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Bunkerhill Contrast CAC regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K260166
  • IndependenceIndependence not established

K260166

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K260166. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-gated, contrast-enhanced chest CT images from adult patients age 30 or older, with slice thickness up to 5 mm.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K260166: Bunkerhill Contrast CAC

  2. Routing

    Source context, not route validation: Interfaces with compatible commercially available CT systems; DICOM CT input and output viewing in a diagnostic viewer/PACS are described. A separate ROI series and optional DICOM Secondary Capture/report insertion are supported in the packet; exact deployment topology is not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K260166: Bunkerhill Contrast CAC

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Informational ROI on a copy of the original CT showing detected coronary calcium; estimated overall calcium volume score in mm3; binary presence/absence output; results can be viewed in a patient report or diagnostic viewer/PACS, with optional copy/insert or DICOM Secondary Capture.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K260166: Bunkerhill Contrast CAC

  5. Viewer/worklist/report

    Unresolved route: Informational ROI on a copy of the original CT showing detected coronary calcium; estimated overall calcium volume score in mm3; binary presence/absence output; results can be viewed in a patient report or diagnostic viewer/PACS, with optional copy/insert or DICOM Secondary Capture.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K260166: Bunkerhill Contrast CAC

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Interfaces with compatible commercially available CT systems; DICOM CT input and output viewing in a diagnostic viewer/PACS are described. A separate ROI series and optional DICOM Secondary Capture/report insertion are supported in the packet; exact deployment topology is not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Bunkerhill Health's website states SOC 2 Type II certification, HIPAA compliance and ISO/IEC 27001:2022 certification. Badges only: no scope, dates or controls are given. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Bunkerhill Contrast CAC; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260166
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest/coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-06
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K260166 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K260166: Bunkerhill Contrast CAC

    U.S. Food and Drug Administration - Published 2026-03-06 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Bunkerhill Contrast CAC model card (K260166)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K260166

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Bunkerhill Health home page security claims

    Bunkerhill Health - Accessed 2026-10-25

    Scope: security

Research history

  1. K260166 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242188

ClearRead CT CAC

Riverain Technologies, Inc.

Authorized purpose: Aids physicians in assessing coronary artery calcification on non-gated, non-contrast standard- or low-dose chest CT.

Modality
CT/CTA
Anatomy
Chest/coronary arteries
Decision
2024-12-03
FDA-cleared K253520

Photonova Spectra, Photonova Spectra Select

Ge Medical Systems, LLC

Authorized purpose: Photonova Spectra and Spectra Select are silicon-based spectral photon-counting detector CT systems that acquire cross-sectional body images, multienergy data, monochromatic images, and material-density maps for labeled head, whole-body, cardiac, vascular, and lung workflows.

Modality
CT/CTA
Anatomy
Head, whole body, heart, vessels, and lungs
Decision
2026-03-20
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history